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Relaxin, a heterodimeric polypeptide hormone, is a key regulator of collagen metabolism
and multiple vascular control pathways in humans and rodents. Its actions are mediated
via its cognate G-protein-coupled receptor, RXFP1 although it also “pharmacologically”
activates RXFP2, the receptor for the related, insulin-like peptide 3 (INSL3), which has
specific actions on reproduction and bone metabolism. Therefore, experimental tools to
facilitate insights into the distinct biological actions of relaxin and INSL3 are required,
particularly for studies of tissues containing both RXFP1 and RXFP2. Here, we chemically
functionalized human (H2) relaxin, the RXFP1-selective relaxin analog H2:A(4-24)(F23A),
and INSL3 to accommodate a fluorophore without marked reduction in binding or
activation propensity. Chemical synthesis of the two chains for each peptide was followed
by sequential regioselective formation of their three disulfide bonds. Click chemistry
conjugation of Cy5.5 at the B-chain N-terminus, with conservation of the disulfide bonds,
yielded analogs displaying appropriate selective binding affinity and ability to activate
RXFP1 and/or RXFP2 in vitro. The in vivo biological activity of Cy5.5-H2 relaxin and
Cy5.5-H2:A(4-24)(F23A) was confirmed in mice, as acute intracerebroventricular (icv)
infusion of these peptides (but not Cy5.5-INSL3) stimulated water drinking, an established
behavioral response elicited by central RXFP1 activation. The central distribution of
Cy5.5-conjugated peptides was examined in mice killed 30min after infusion, revealing
higher fluorescence within brain tissue near-adjacent to the cerebral ventricle walls
relative to deeper brain areas. Production of fluorophore-conjugated relaxin family peptides
will facilitate future pharmacological studies to probe the function of H2 relaxin/RXFP1
and INSL3/RXFP2 signaling in vivo while tracking their distribution following central or
peripheral administration.
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INTRODUCTION
Relaxin is a peptide hormone that has long been recognized for
its pleiotropic roles in peripheral tissues, especially during preg-
nancy (Hisaw, 1926; Bathgate et al., 2013). It is a 53 amino acid
peptide (6 kDa) that comprises two chains (A and B) and three
disulfide bonds, one intramolecular disulfide bond within the A-
chain and two others linking the A- and B-chains (Shabanpoor
et al., 2009; Chan et al., 2011). In addition to its roles in repro-
ductive physiology, relaxin (designatedH2 relaxin in humans) has
physiological and therapeutic vasodilatory, cardio-protective and
anti-fibrotic actions in animals and human. In fact, the peptide
has recently passed Phase III clinical trials for the treatment of
acute heart failure (Teerlink et al., 2013).
Relaxin is mainly produced in the corpus luteum during preg-
nancy, but is also present in the placenta and prostate gland, in
addition to a host of non-reproductive tissues including the brain
(Shabanpoor et al., 2009; Bathgate et al., 2013). It interacts with
relaxin family peptide receptor 1 (RXFP1), a G-protein-coupled
receptor, to exert its biological effects. In experimental systems
H2 relaxin also interacts with RXFP2, which is structurally simi-
lar to RXFP1 (Hsu et al., 2002), and is the native receptor for the
related peptide, insulin-like peptide 3 (INSL3) (Kumagai et al.,
2002) although there is no strong evidence that this interaction is
physiologically significant (Bogatcheva et al., 2003; Kamat et al.,
2004). Relaxin displays no cross-reactivity for RXFP3 and RXFP4,
the receptors for relaxin-3 and insulin-like peptide 5 (INSL5)
(Shabanpoor et al., 2009). The cardio-protective effects of H2
relaxin are known to be mediated by RXFP1 (Du et al., 2010).
Relaxin and RXFP1 are present in a number of different regions of
the rat (Osheroff and Phillips, 1991; Ma and Gundlach, 2007) and
mouse (Piccenna et al., 2005) brain, but their role there has not
been clearly identified. Several investigators have reported that
intracerebroventricular (icv) infusion of H2 relaxin in rodents
induces a drinking (dipsogenic) response, which is thought to be
mediated via activation of RXFP1 expressed by neurons in the cir-
cumventricular organs, such as the subfornical organ (Summerlee
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et al., 1998; Sunn et al., 2002). However, the function of receptors
within deeper brain tissue more distal to the ventricle wall is not
known nor is it known to what degree these receptors are accessed
following infusion of H2 relaxin via the icv route. Similarly, the
INSL3 receptor, RXFP2, is expressed within regions of the rat and
mouse brain both proximal and distal to the ventricular system
(Sedaghat et al., 2008), but little data has been reported on their
function.
In this regard, examining the behavior of rodents following
infusion of receptor-selective peptide ligands into the cerebral
ventricular system or local brain regions has revealed that another
relaxin family peptide receptor, RXFP3, has various putative cen-
tral functional roles (McGowan et al., 2007; Ma et al., 2009;
Tanaka, 2010; Ryan et al., 2013). Similar experimental approaches
may be equally valuable for determining the central role of H2
relaxin/RXFP1 and INSL3/RXFP2 signaling. In pursuit of this
goal, our recent structure-function studies led to the development
of an RXFP1-selective H2 relaxin analog, H2:A(4-24)(F23A)
(Chan et al., 2012). However, interpretation of studies involv-
ing infusions of H2 relaxin, H2:A(4-24)(F23A) or INSL3 into the
rodent brain is currently hampered by an inability to determine
how readily these peptides penetrate and spread throughout brain
tissue. Such information is ultimately important, as although
injected peptides are often thought to “bathe the whole brain”
when delivered icv, this assumption is usually not tested.
In studies to address this long-term goal for the relaxin peptide
family, we have prepared functionally active fluorescent analogs
of H2 relaxin, H2:A(4-24)(F23A) and INSL3. This required care-
ful design and development as most available fluorophores are
large, bulky molecules and may potentially mask the active site
of the peptide leading to significant or complete loss of activ-
ity. Furthermore, it is important to consider the possibility of an
adverse impact upon brain distribution. Using chemical peptide
synthesis methods and regioselective disulfide bond formation,
we assembled cyanine 5.5 (Cy5.5) fluorophore-conjugated H2
relaxin (Cy5.5-H2 relaxin), which retains high affinity for RXFP1
and RXFP2. Synthetic RXFP1- and RXFP2-specific analogs,
namely Cy5.5-H2:A(4-24)(F23A) and Cy5.5-INSL3, respectively,
were also prepared. Attachment of the Cy5.5 fluorophore was
achieved by post-synthesis azide-alkyne Huisgen cycloaddition
“click chemistry,” an effective method for labeling at a specific
site within these cysteine-rich relaxin family peptide analogs
(Kolb et al., 2001). The biological activity of Cy5.5-H2 relaxin
and Cy5.5-H2:A(4-24)(F23A) was then confirmed by observing a
dipsogenic response following icv infusion, and subsequent his-
tological analysis of brains harvested 30min post icv infusion
revealed high concentrations of all three peptides in brain gray
matter adjacent to the cerebral ventricle wall.
MATERIALS AND METHODS
SOLID PHASE PEPTIDE SYNTHESIS
Individual A- and B-chains of H2 relaxin, H2:A(4-24)(F23A) and
INSL3 with appropriate regioselective S-protection were synthe-
sized using either continuous flow or microwave-assisted solid
phase methodologies on an automated PerSeptives Biosystems
Pioneer peptide synthesizer and a CEM Liberty peptide synthe-
sizer, respectively (Hossain et al., 2008b, 2009). Upon complete
coupling of the final amino acid of the native peptide sequence,
an extra amino acid containing the alkyne group (Fmoc-L-
propargylglycine) was attached using manual coupling proce-
dures. Following simultaneous cleavage, side chain deprotection
and purification of crude A- and B-chains, stepwise formation
of the three disulfide bonds was conducted via oxidation, thiol-
ysis and iodolysis consecutively (Bathgate et al., 2006; Hossain
et al., 2006, 2008a; Zhang et al., 2008). The resulting synthesized
relaxin family analogs had their B-chains functionalized with a
propargylglycine containing an alkyne group at the N-terminus
(Figure 1).
CLICK CHEMISTRY: ATTACHMENT OF Cy5.5 FLUOROPHORE TO RELAXIN
FAMILY ANALOGS
Cy5.5 fluorophore bearing an azide moiety (Lumiprobe,
Hallendale Beach, FL, USA) was coupled to alkyne-functionalized
H2 relaxin, H2:A(4-24)(F23A) or INSL3 peptides via click chem-
istry. The alkyne peptide (50μg) was firstly dissolved in 2M
triethylammonium acetate buffer, pH 7. Next, 2 equivalents of
Cy5.5 azide dissolved in dimethyl sulfoxide (DMSO) was added
and the reaction was left for 10min at room temperature. The
addition of 21 equivalents of copper (II) sulfate pentahydrate dis-
solved in dH2O and 21 equivalents of ascorbic acid dissolved
in dH2O were added to the reaction mixture and stirred for an
hour at room temperature. The reaction mixture was then diluted
with 80μl of dH2O before being injected onto RP-HPLC for
purification.
PEPTIDE CHARACTERIZATION
Peptides were purified using RP-HPLC via a preparative col-
umn while the final purity of individual synthetic peptides was
assessed by analytical RP-HPLC using a Vydac C18 column
(250 × 4.6mm, 300Å, 5μm) with a buffer system of 0.1% triflu-
oroacetic acid in dH2O (buffer A) and 0.1% trifluoroacetic acid in
acetonitrile (buffer B). The molecular masses of all analogs were
determined by MALDI-TOF mass spectrometry using a Bruker
FIGURE 1 | Amino acid sequence of native H2 relaxin and INSL3 and
synthetic Cy5.5 analogs.
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AutoflexII instrument in the linear mode at 19.5 kV. Furthermore,
the peptide content for each analog was quantified by amino acid
analysis using vapor-phase acid hydrolysis in 6M hydrochloric
acid containing 2% phenol at 110◦C over 24 h. The hydrolysate
was then converted to stable, fluorescent derivatives using a
Waters AccQTag kit. The derivitized amino acids were separated
using a Shim-Pak XR ODS column (3 × 75mm, 2.2μm) on a
Shimadzu microbore RP-HPLC system.
LIGAND BINDING ASSAY
Human embryonic kidney (HEK-293T) cells stably transfected
with RXFP1 or RXFP2 were cultured in RPMI 1640 medium
supplemented with 10% fetal calf serum, 100μg/ml penicillin,
100μg/ml streptomycin, and 2mM L-glutamine and plated into
96-well plates pre-coated with poly-L-lysine for whole cell bind-
ing assays. Competition binding experiments were conducted
with either Eu3+-labeled H2 relaxin (Shabanpoor et al., 2012)
or Eu3+-labeled INSL3 (Shabanpoor et al., 2008) in the absence
or presence of increasing concentrations of unlabeled relaxin
peptide analogs. Non-specific binding was determined in the
presence of an excess of unlabeled peptides (500 nM relaxin or
INSL3). Fluorescence measurements were recorded at an exci-
tation wavelength of 340 nm and emission of 614 nm. All data
are presented as the mean ± SE of the percentage of total spe-
cific binding of triplicate wells, repeated in at least three separate
experiments, and curves were fitted using one-site binding curves
in GraphPad Prism 4. Statistical differences in pEC50 values were
analyzed using One-Way analysis of variance (ANOVA) coupled
to the Newman Keul’s multiple comparison test for multiple
group comparisons in GraphPad Prism 4.
FUNCTIONAL cAMP ASSAY
The ability of the Cy5.5-labeled insulin/relaxin family peptide
analogs to stimulate cAMP production was evaluated using a
cAMP reporter gene assay as described (Scott et al., 2006). HEK-
293T cells co-transfected with either RXFP1 or RXFP2 and a
pCRE β-galactosidase reporter plasmid were plated in 96-well
plates (Chen et al., 1995). After 24 h, the co-transfected cells
were incubated with increasing concentrations of relaxin analogs
in parallel to 10 nM of H2 relaxin or INSL3 for RXFP1- or
RXFP2- transfected cells, respectively. The amount of cAMP-
driven β-galactosidase expression in each well was assessed
with a colormetric assay measuring absorbance at 570 nm on
a microplate spectrophotometer. Ligand-induced cAMP stim-
ulation was expressed as a percentage of maximal response
of H2 relaxin or INSL3 for RXFP1 and RXFP2 cells, respec-
tively. Each data point was measured in triplicate and each
experiment conducted independently at least three separate
times. Statistical differences in pEC50 values were analyzed using
One-Way ANOVA coupled to the Newman Keul’s multiple
comparison test for multiple group comparisons in GraphPad
Prism 4.
STEREOTAXIC IMPLANTATION OF GUIDE CANNULA FOR CENTRAL
ADMINISTRATION OF PEPTIDES
Adultmale C57B/6Jmice (10-weeks old) were deeply anesthetized
by inhalation of 4% isoflurane and anaesthesia was maintained
with 2% isoflurane administered at 0.2 l/min through a nasal
cone. Mice were secured in a stereotaxic frame and an incision
made to expose the skull, which was cleaned with 6% hydrogen
peroxide. Two 1mm-diameter holes were drilled in the skull on
either side of the sagittal midline, 3mm posterior and 3mm lat-
eral to bregma, to allow small screws (3mm long) to be secured
in order to anchor the guide cannula in place. A third hole of
1mm in diameter was drilled through the skull to allow implanta-
tion of a stainless-steel guide cannula (11mm long, 24 gauge) just
above the lateral ventricle at the coordinates relative to bregma:
anterior-posterior −0.46mm; medial-lateral −0.8mm; dorsal-
ventral −1.8mm. The guide cannula and screws were fixed in
place by application of self-curing acrylic dental cement (Vertex-
Dental, the Netherlands).
INTRACEREBROVENTRICULAR INFUSION OF RELAXIN FAMILY
PEPTIDES
After 5–10 days recovery post-surgery, mice were gently restrained
and an injector was inserted through the guide cannula which
protruded 0.5mm into the lateral ventricle. A single 4μg dose
of each peptide (n = 3–4) was delivered in 4μl of artificial
CSF (aCSF; 147mM NaCl, 4mM KCl, 0.85mM MgCl2, and
2.3mM CaCl2), over 1min via a 10μl syringe (0.46mm diam-
eter) mounted on an infusion pump connected to the injector via
polyethylene tubing. Following infusion, the injector was left in
place for a further 15 s to prevent backflow of the infused peptide
up the guide cannula.
BEHAVIORAL TESTING AND BRAIN PROCESSING
Following peptide infusion, mice were placed back in their clear-
walled home cages for 30min with access to water (and food)
and filmed through the side of the cage for subsequent assess-
ment of behavior. After 30min, mice were killed by isoflurane
inhalation overdose, decapitated, and brains were removed and
“post-fixed” by immersion in chilled 4% PFA solution. After fix-
ation at 4◦C for 48 h, brains were then transferred to a 20%
sucrose solution for cryoprotection at 4◦C overnight. Brains were
then coated with OCT embedding medium, frozen on dry ice
and stored at −80◦C. Coronal sections (40μm) were cut on a
cryostat at −19◦C through the rostrocaudal brain axis, slide-
mounted and coverslipped with fluorescent mounting media.
Sections were viewed and images collected using a confocal laser
scanning microscope, using laser light at λ of 633 nm, while light
between λ of 650–750 nm was detected.
RESULTS AND DISCUSSION
The A- and B-chains of H2 relaxin, H2:A(4-24)(F23A), and
INSL3 peptides (Figure 1) were synthesized on solid support
using Fmoc-SPPS chemistry (Atherton and Sheppard, 1998). An
alkyne residue (L-propargylglycine) was coupled to the native
B-chain sequences at the N-terminus (Figure 2). Our estab-
lished regioselective disulfide formation chemical approach was
utilized to assemble these two-chain peptides with three differ-
ential cysteine S-protecting groups (Trt, tBu, and Acm) used to
assist the direct formation of the three disulfide bonds (Bathgate
et al., 2006; Hossain et al., 2008a; Zhang et al., 2008). Each
peptide was obtained in good overall yields (10–14% relative
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FIGURE 2 | General schematic representation of the formation of the
Cy5.5 analogs. In step 1, an Fmoc-L-propargylglycine residue with an alkyne
moiety was attached at the N-terminus of the B-chain on solid phase and
then cleaved from the resin. In step 2, the propargylglycine B-chain was
combined with the A-chain, together with the formation of the interdisulfide
bonds to give the alkyne product. In step 3, under a copper-catalyzed
reaction, the formation of a stable triazole bond between an alkyne and azide
group was able to proceed, leading to the formation of the Cy5.5 product of
interest. Analytical RPLC was undertaken on a Vydac C18 column
(250 × 4.6mm, 300Å, 5μm) with a buffer system of 0.1% trifluoroacetic acid
in water (buffer A) and 0.1% trifluoroacetic acid in acetonitrile (buffer B).
Elution was with a gradient of 20–50% B over 30min.
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to starting B-chain material) and was subjected to comprehen-
sive characterization by RP-HPLC and MALDI-TOF mass spec-
trometry to confirm its high purity and correct molecular mass
(Table 1).
Three peptides [H2 relaxin, H2:A(4-24)(F23A) and INSL3]
were successfully labeled in solution with Cy5.5, using the ver-
satile method of click chemistry (Figure 2) (Best, 2009). In this
study, the click reaction was used for bioconjugation to enable
the labeling of alkyne-functionalized relaxin family peptides with
Cy5.5, a fluorescent tag bearing an azide moiety. The Cy5.5 fluo-
rophore was chosen due to its favorable properties. Specifically, it
emits in the far red region of the electromagnetic spectrum (exci-
tation maximum, λmaxex = 673 nm; Cy5.5 emission maximum,
λmax
fluor = 707 nm) and provides a high signal to noise ratio in
tissue studies, as biological specimens and tissues usually have low
autofluorescence in this spectral region. The Cy5.5 fluorophore is
also compatible for use with more commonly used fluorophores
that emit in the blue, green and red spectra, thus allowing for easy
labeling and localization of two or more labels in cells and tissues.
Our previous studies revealed that attachment of biotin to the N-
terminus of the H2 relaxin B-chain via an amide bond resulted
in a synthetic H2 relaxin analog able to retain near-native activity
(Mathieu et al., 2001). This result indicated that the bulky biotin
molecule was far enough away from the known peptide active site
region, to avoid any marked effect on its receptor binding and
activation properties. Therefore, the Cy5.5 fluorophore was click
conjugated to the N-terminus of the B-chain of the peptides. The
alkynemoiety of native H2 relaxin, H2:A(4-24)(F23A) and INSL3
reacted with the azide moiety of the Cy5.5 fluorophore forming a
triazole ring. Comprehensive characterization by RP-HPLC and
MALDI-TOF mass spectrometry confirmed the expected puri-
ties and identities (Table 1). Importantly, the data provided no
evidence that the conjugation conditions caused a reduction of
any of the disulfide bonds or other deleterious side reactions. To
our knowledge, this is the first report of a successful copper (II)-
mediated Huisgen cycloaddition in the presence of preformed
disulfide bonds.
Established cell-based assays were used to evaluate the inter-
action of the fluorescent analogs at RXFP1 and RXFP2. Both
native H2 relaxin and the labeled Cy5.5-H2 relaxin bound to and
activated both RXFP1 and RXFP2 (Figure 3). As predicted, the
H2 relaxin analog, Cy5.5-H2:A(4-24)(F23A), selectively bound
to and activated RXFP1 (Figures 3A,B). In contrast, INSL3 and
its labeled analog, Cy5.5-INSL3, only bound to and activated
RXFP2 (Figures 3C,D). Notably, due to the addition of the
Cy5.5 fluorophore at the N-terminus of the B-chain, the affin-
ity/potency of all labeled analogs was not markedly reduced
relative to the native peptides (Figure 3 and Table 1).
It is well established that central activation of RXFP1 (specif-
ically, in the circumventricular organs) confers a dipsogenic
response in rodents comparable in magnitude to that elicited
by angiotensin II (Harland et al., 1988; Sunn et al., 2002). Icv
infusion of Cy5.5-H2 relaxin and Cy5.5-H2:A(4-24)(F23A) stim-
ulated a similar increase in drinking behavior which occurred
between 10 and 15 s after mice were placed back into their cages,
confirming the in vivo biological activity of these peptides (see
video in Supplementary Material). In contrast, icv infusion of
Cy5.5-INSL3 did not initiate a drinking response. These data
confirm a predicted aspect of in vivo specificity of Cy5.5-INSL3,
i.e., a lack of cross reactivity with RXFP1. But once a clear, repro-
ducible behavioral response in mice to RXFP2 activation has
been established, it would be important to determine whether
icv injection of Cy5.5-INSL3 confers a similar response (see also
below).
Subsequent histological visualization revealed that 30min
after icv injection of Cy5.5-H2 relaxin, high levels of Cy5.5 were
present within the ventricle wall and brain tissue proximal to
the major cerebral ventricles, including the subfornical organ
(Figures 4A–F). At this time point, a diminishing concentration
gradient was evident, with brain tissue further than 300μm from
the ventricle wall displaying little or no Cy5.5 fluorescence that
was clearly distinguishable from background fluorescence and/or
that displayed a clear correlation with the known distribution of
RXFP1. Indeed, a similar “peri-ventricular” distribution pattern
and relative signal strength was observed following icv infusion
of Cy5.5-H2:A(4-24)(F23A) and Cy5.5-INSL3 (Figures 4G,H).
Although it is possible that addition of the Cy5.5 fluorophore
may impede the diffusion of these peptides within the brain,
such effects are likely to be minimal based on the relatively small
size of Cy5.5, compared to the three relaxin family analogs (ca.
6000Da). Hence the observed distribution of the Cy5.5 fluores-
cence should be representative of the distribution of the labeled
and the equivalent unlabeled peptides.
These data and earlier studies suggest, however, that although
peptides are transported rapidly through the cerebrospinal
fluid following icv infusion, all brain structures are not uni-
formly reached by relaxin family analogs, and hence analysis
of any behavioral responses should be interpreted accordingly.
Table 1 | Competition binding (pKi) and activation (pEC50) by H2 relaxin analogs of RXFP1, and by INSL3 analogs of RXFP2, and molecular
weight of peptides.
Peptide RXFP1 RXFP2 MW
pKi pEC50 pKi pEC50 Calculated Observed
Native H2 relaxin 9.45 ± 0.14 10.71 ± 0.14 ND ND 5961.23 5960.33
Cy5.5-H2 relaxin 7.79 ± 0.26 8.99 ± 0.23 ND ND 6781.25 6780.81
Cy5.5-H2:A(4-24)(F23A) 7.63 ± 0.25 8.61 ± 0.06 NA NA 6301.61 6301.68
Native INSL3 NA NA 9.09 ± 0.22 10.40 ± 0.07 6778.54 6279.46
Cy5.5-INSL3 NA NA 8.21 ± 0.28 9.01 ± 0.22 7100.38 7100.15
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FIGURE 3 | Activity of Cy5.5 insulin/relaxin family peptide analogs at
RXFP1 or RXFP2. (A) Competition binding of native relaxin and Cy5.5-H2
relaxin analogs in the presence of the competitive ligand Eu3+-labeled H2
relaxin tested in HEK-293T cells stably expressing RXFP1. (B) Effect of
native H2 relaxin and Cy5.5-H2 relaxin analogs on cAMP-related activity in
HEK-293T cells expressing RXFP1 using a pCRE-galactosidase reporter
gene system. (C) Competition binding of native INSL3 and Cy5.5-INSL3 in
the presence of the competitive ligand Eu3+-labeled INSL3 tested in
HEK-293T cells stably expressing RXFP2. (D) Effect of native INSL3 and
Cy5.5-INSL3 on cAMP activity in HEK-293T cells expressing RXFP2 using a
pCRE-galactosidase reporter gene system. Data are expressed as a
percentage of specific binding or maximum relaxin/INSL3-stimulated cAMP
response and are pooled data from at least three experiments performed
in triplicate.
For example, in situ hybridization (Piccenna et al., 2005) and
radioligand binding studies (Ma et al., 2006) have revealed that
RXFP1 mRNA/binding sites are broadly distributed within the
rodent brain including high densities in the olfactory bulb,
cortex, hippocampus and subiculum, amygdala, circumventric-
ular organs, thalamus, hypothalamus, and brainstem (Ma and
Gundlach, 2007; Gundlach et al., 2009). This broad distribution
suggests that relaxin/RXFP1 signaling modulates a diverse range
of neural circuits, although the nature of this modulation and
the relative role of endogenously/locally produced relaxin vs. any
effects of circulating relaxin are not known. In fact, studies of
the effects of icv infusion of H2 relaxin have thus far linked cen-
tral RXFP1 activation with relatively few behavioral responses
[e.g., (Summerlee et al., 1998; McGowan et al., 2010)], while local
infusion of H2 relaxin into a deeper area of the rat brain, the baso-
lateral amygdala, produced effects on fear memory (Ma et al.,
2005). Notably, the diffusion and distribution of the H2 relaxin
was not monitored in the former icv studies, whereas injection of
H2 relaxin into an adjacent area of the amygdala (central nucleus)
was without effect in the latter study.
Similarly, although INSL3/RXFP2 signaling is best charac-
terized for its roles in peripheral tissues and in reproduction
(Bogatcheva et al., 2003; Kamat et al., 2004; Ferlin et al., 2006;
Bathgate et al., 2013), RXFP2 is also broadly expressed within cor-
tical, striatal, thalamic, and hypothalamic areas of rodent brain
(Sedaghat et al., 2008; Gundlach et al., 2009). Currently, the
effects of central INSL3/RXFP2 activation remain largely unre-
ported, and studies in this area should benefit from the availability
of Cy5.5-INSL3.
The approach used here to label H2 relaxin, H2:A(4-24)(F23A)
and INSL3 might also be applied to other relaxin family mem-
bers, as icv infusion of H3 relaxin and analogs modulates feeding
via interactions with RXFP3 within the hypothalamus (McGowan
et al., 2007; Ganella et al., 2012), while local infusions of RXFP3
agonist or antagonist peptides into the medial septum alters spa-
tial memory (Ma et al., 2009). Overall, these studies indicate that
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FIGURE 4 | Fluorescent confocal micrographs of coronal sections
from brains harvested 30min after icv infusion, which demonstrate
Cy5.5-H2 relaxin (A–F), Cy5.5-H2:A(4-24)(F23A) (G) and Cy5.5-INSL3
(H) highly concentrated within brain tissue proximal to the
cerebral ventricle wall. Rostral-dorsal location, relative to bregma
(mm): (A) 0.38; (B) −4.96; (C) −6.24; (D) −0.82; (E,F) −0.46; (G)
0.86; (H) −4.84. Scale bars, (A–D,G,H) 300μm; (E) 100μm; (F)
50μm. The region in (E) designated by the square is magnified in
(F). Abbreviations: 2/10cb, 2nd, and 10th cerebellar lobules; 3V/4V, 3rd
and 4th ventricle; AHC, anterior hypothalamic area, central part; Aq,
aqueduct; D3V, dorsal 3rd ventricle; LPAG, lateral periaqueductal gray;
LS, lateral septum; LV, lateral ventricle; Pr, prepositus nucleus; PVN,
paraventricular hypothalamic nucleus; SFO, subfornical organ; vhc,
ventral hippocampal commissure.
behaviors altered following icv infusion of relaxin family peptides
(and other peptides) may represent actions mediated by activated
or inhibited receptor populations proximal to the main cerebral
ventricular system.
However, although a bias may exist for the modulation of
receptors near the ventricular wall, it is possible that receptors in
deeper brain structures are occupied by peptides administered icv.
In a recent study that addressed this issue directly using a similar
protocol and time frame, fluorophore-conjugated neuropeptide S
(NPS) was observed bound to NPS receptor-positive neurons in
deep brain areas at levels well above that of the surrounding tis-
sue after icv and intranasal administration (Ionescu et al., 2012).
Similar studies could be conducted using fluorophore-conjugated
relaxin family analogs. If the dose, route of administration and
timing of the analysis can be optimized, receptor bound pep-
tides may be identified bound to, or within, RXFP1 or RXFP2-
expressing neurons. Clearly these studies would benefit from an
ability to “label” RXFP1- or RXFP2-positive neurons using either
immunohistochemistry or transgenic reporter mouse strains, as
currently detection of Cy5.5 associated with individual neurons
(even in the subfornical organ) is difficult. If successful, however,
these studies might provide insights into whether H2 relaxin or
INSL3 is internalized after binding to RXFP1 and RXFP2 in vivo,
as in vitro studies suggest that this is not the case (Callander
et al., 2009). Cy5.5-peptides could also help determine whether
the changes in neuronal activity observed following icv infusion
of H2-relaxin (via Fos immunostaining) (McKinley et al., 1997)
are the result of direct or indirect RXFP1 (or RXFP2) signaling.
Further studies may also benefit from utilizing different meth-
ods of tissue processing to the paraformaldehyde “post-fixation”
technique used here. Although this method allowed a “snap shot”
visualization of the peptide distribution, the vast majority of flu-
orophore/peptide fixed within the brain tissue was not enriched
on/within neurons—a pattern which, if observed, might have
reflected binding to RXFP1 or RXFP2. Indeed, the presence of
covalently cross-linked peptide fixed within surrounding tissue
may provide unwanted background signal that hampers the visu-
alization of peptides specifically bound to neurons, particularly
in periventricular regions such as the subfornical organ where
such background signal was high. It is possible that the level
of non-specifically bound peptides could be reduced by a brief
(optimized) perfusion of the brain with buffered saline prior
to removal, followed by freezing, and subsequent post-fixing of
slide-mounted sections.
In addition to studies employing the icv route of admin-
istration, tracking the degree of peptide diffusion/spread, and
confirming the correct location of an injection in a target area
is also important for studies of local peptide injections. Cy5.5-
peptides can also be used in combination with real-time whole
animal fluorescent imagers, to determine the rate at which relaxin
family analogs cross the blood brain barrier and enter the brain
following systemic infusion.
CONCLUSION
These studies demonstrate the utility of synthetic chemistry
to generate fluorophore-conjugated relaxin family analogs that
retain activity and good receptor selectivity in vitro and in vivo.
The fluorophore can be used to visualize the location/distribution
of these peptides in biological tissues, which avoids the dis-
advantages of using radiolabeled analogs with their associated
safety hazard and possible short half-life. Here we observed
that Cy5.5-conjugated relaxin family peptides administrated icv
into mice displayed an appropriate profile of acute biological
activity and at 30min post-infusion accumulated within brain
regions proximal to the cerebral ventricular system; however, fur-
ther optimized studies are required to visualize specific receptor
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occupation on/within neurons. In summary, we describe the gen-
eration of novel chemical tools to further probe the function of
H2 relaxin/RXFP1 and INSL3/RXFP2 signaling that offer charac-
teristics which can assist in the interpretation of pharmacological
studies both in vitro and in vivo.
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